Bicara Therapeutics

Aura Biosciences

This biotechnology company develops virus-like drug conjugates to treat patients with solid tumours, specifically targeting ocular and bladder cancers.

A2 Biotherapeutics

This company develops logic-gated T-cell therapies to treat patients with solid tumours by selectively targeting cancer cells while sparing healthy tissue.

Bicycle Therapeutics

This biopharmaceutical company develops synthetic bicyclic peptide medicines to treat solid tumours and other diseases for patients with unmet medical needs.

Xilio Therapeutics

This biotechnology company develops tumour-activated immuno-oncology therapies designed to treat patients with solid cancers while reducing systemic side effects.

Tango Therapeutics

This biotechnology company develops precision oncology medicines targeting genetic vulnerabilities in cancer cells for patients with solid tumours.

Daylight Biotherapeutics

This company develops T-cell engaging therapies for cancer patients to eliminate tumours while reducing systemic immune toxicity.

Actym Therapeutics

This biotechnology company develops bacterial immunotherapies to treat solid tumours and fibrotic diseases for patients with advanced cancers.

TwoStep Therapeutics

The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.